Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lercanidipine and Valsartan Combination in Essential Hypertension
NCT01122251Phase 2Completed
- Sponsor
- LG Chem
- Start
- Dec 2009
- Primary completion
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in essential hypertension comparing Lercanidpine + Valsartan, Lercanidipine or Valsartan and Placebo (3 arms). Primary endpoint: Sitting Diastolic Blood Pressure at 8 weeks. Started Dec 2009; status: completed.
02
Drugs
lercanidipinevalsartan
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT01122251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01122251.